Corcillo Antonella, Pivin Edward, Lalubin Fabrice, Pitteloud Nelly, Burnier Michel, Zanchi Anne
Service of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Service of Nephrology and Hypertension, Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Swiss Med Wkly. 2017 Jul 6;147:w14459. doi: 10.4414/smw.2017.14459. eCollection 2017.
The prevalence of chronic kidney disease and diabetes is rising in Europe. These patients are at high cardiovascular and renal risk and need a challenging multifactorial therapeutic approach.
The goal of this cross-sectional study was to examine the treatment and attainments of goals related to cardiovascular risk factors within chronic kidney disease stages in type 2 diabetic patients followed up by primary care physicians in Switzerland. Each participating physician entered into a web database the anonymised data of up to 15 consecutive diabetic patients attending her/his office between December 2013 and June 2014. Diabetes, hypertension and lipid lowering therapies were analysed, as well as glycated haemoglobin (HbA1c), blood pressure and low-density lipoprotein-cholesterol (LDL-c) levels and goal attainments by KDIGO chronic kidney disease stage 1 to 4.
A total of 1359 patients (mean age 66.5±12.4 years) were included by 109 primary care physicians. Chronic kidney disease stages 0-2, 3a, 3 b and 4 were present in 77.6%, 13.9%, 6.1%, and 2.4%, respectively. Average HbA1c was independent of chronic kidney disease stage and close to 7%; more than half of the patients reached the HbA1c goal. Eighty-four percent of patients were hypertensive and only 18.2% reached the then current Swiss or American Diabetes Association 2013 blood pressure goals. Despite loosening of blood pressure goals in 2015, only half of the patients reached them and most needed multiple therapies. Increased body mass index and advanced chronic kidney disease stage decreased the chance of reaching blood pressure goals. Lipid lowering therapy was prescribed in 62.1% of cases, with average LDL-c levels similar across chronic kidney disease stages. Only 42% of patients reached the LDL-c goal of <2.5 mmol/l in primary prevention and 32% reached <1.8 mmol/l in secondary prevention. Younger patients were treated significantly less aggressively than older patients (≥68 years, median age) for HbA1c, LDL-c and diastolic blood pressure control.
This cross-sectional study demonstrates that blood pressure and lipid goals are less often achieved than blood glucose control in type 2 diabetic patients followed up by primary care physicians in Switzerland. Goal attainments for HbA1c and LDL-c were not influenced by chronic kidney disease stages, in contrast to blood pressure. Reaching all three goals was rare (2.2%). There is a need for improvement in blood pressure control in advanced chronic kidney disease, whereas HbA1c goals may be loosened in the elderly and in advanced chronic kidney disease.
欧洲慢性肾脏病和糖尿病的患病率正在上升。这些患者面临较高的心血管和肾脏风险,需要采取具有挑战性的多因素治疗方法。
这项横断面研究的目的是检查瑞士初级保健医生随访的2型糖尿病患者在慢性肾脏病各阶段中与心血管危险因素相关的治疗及目标达成情况。每位参与的医生将2013年12月至2014年6月期间在其诊所就诊的最多15例连续糖尿病患者的匿名数据录入网络数据库。分析了糖尿病、高血压和降脂治疗情况,以及糖化血红蛋白(HbA1c)、血压和低密度脂蛋白胆固醇(LDL-c)水平,以及根据KDIGO慢性肾脏病1至4期的目标达成情况。
109名初级保健医生共纳入1359例患者(平均年龄66.5±12.4岁)。慢性肾脏病0 - 2期、3a期、3b期和4期分别占77.6%、13.9%、6.1%和2.4%。平均HbA1c与慢性肾脏病分期无关,接近7%;超过一半的患者达到了HbA1c目标。84%的患者患有高血压,只有18.2%的患者达到了当时瑞士或美国糖尿病协会2013年的血压目标。尽管2015年血压目标有所放宽,但只有一半的患者达到目标,且大多数患者需要多种治疗。体重指数增加和慢性肾脏病晚期降低了达到血压目标的几率。62.1%的病例进行了降脂治疗,各慢性肾脏病分期的平均LDL-c水平相似。在一级预防中,只有42%的患者达到LDL-c目标<2.5 mmol/l,在二级预防中,32%的患者达到<1.8 mmol/l。在HbA1c、LDL-c和舒张压控制方面,年轻患者的治疗力度明显低于老年患者(≥68岁,中位年龄)。
这项横断面研究表明,在瑞士初级保健医生随访的2型糖尿病患者中,血压和血脂目标的达成情况不如血糖控制。与血压不同,HbA1c和LDL-c的目标达成情况不受慢性肾脏病分期的影响。同时达到所有三个目标的情况很少见(2.2%)。晚期慢性肾脏病患者的血压控制需要改善,而在老年人和晚期慢性肾脏病患者中,HbA1c目标可能需要放宽。